Literature DB >> 10884005

Endogenous attention and illusory line motion reexamined.

W C Schmidt1.   

Abstract

P. Downing and A. Treisman's (1997) failure to replicate an effect of endogenous attention on the direction of illusory line motion (ILM) was reexamined. Four experiments with slightly modified stimulus presentation methods based on gradient theories of ILM found that endogenous attention directed to 1 of 2 similar priming objects is capable of influencing experienced motion direction within a subsequently presented line. The endogenous effect on ILM was consistent with a concomitant response-time discrimination task, was robust across naive and informed participants, occurred whether eye fixation was monitored or not, and occurred under conditions where multiple motion response categories were available to participants. The endogenous effect disappeared when participants moved their eyes to the attended item, when there was no motivation to endogenously attend, and when the presentation methods of P. Downing and A. Treisman (1997) were used.

Entities:  

Mesh:

Year:  2000        PMID: 10884005     DOI: 10.1037//0096-1523.26.3.980

Source DB:  PubMed          Journal:  J Exp Psychol Hum Percept Perform        ISSN: 0096-1523            Impact factor:   3.332


  4 in total

1.  Displacement of location in illusory line motion.

Authors:  Timothy L Hubbard; Susan E Ruppel
Journal:  Psychol Res       Date:  2012-03-08

2.  Perceptual consequences of visual performance fields: the case of the line motion illusion.

Authors:  Stuart Fuller; Marisa Carrasco
Journal:  J Vis       Date:  2009-04-17       Impact factor: 2.240

3.  Does Allocation of Attention Influence Relative Velocity and Strength of Illusory Line Motion?

Authors:  Timothy L Hubbard; Susan E Ruppel
Journal:  Front Psychol       Date:  2018-02-22

4.  No prior entry for threat-related faces: evidence from temporal order judgments.

Authors:  Antonio Schettino; Tom Loeys; Gilles Pourtois
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.